Please use this identifier to cite or link to this item:
|Title:||Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation||Authors:||Forsyth, Cecily J ;Joshi, M.;Taper, J.;Rowlings, P.;Campbell, P.;Crispin, P.;Harvey, M.;Underhill, C.;Bayley, A.;Byth, K.;Huang, G.;Hertzberg, M.||Affliation:||Central Coast Local Health District
|Issue Date:||Sep-2019||Source:||61(1):91-97||Journal title:||Leukemia & lymphoma||Department:||Haematology||Abstract:||Patients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) ineligible for autologous stem cell transplantation (autoSCT) have poor survival. Thirty transplant-ineligible patients older than 60 years were administered rituximab 375 mg/m2 day 1, ifosfamide 1333 mg/m(2) days 1 to 3, and etoposide 80 mg/m(2) days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3-4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3-4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1667||DOI:||10.1080/10428194.2019.1660968||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/31512531||ISSN:||1026-8022||Publicaton type:||Journal Article||Keywords:||Haematology
|Appears in Collections:||Haematology|
Show full item record
checked on Jan 27, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.